A study on the effects of the alcohol on the patients with type 2 diabetes at the Huazhong University of Science and Technology shows that the wine is more helpful when compared with beer or spirit for the patients with type 2 diabetes.
There may be a greater risk of severe hypoglycemia if more alcohol is consumed. The lead author of the study was Dr. Jin Huang. The results were published in the Journal of Diabetes Investigation.
iGlarLixi is a combination drug for the treatment of type 2 diabetes (T2D). This drug is manufactured by the Zealand Pharma A/S. This drug was recommended for approval by the US panel.
Manufacturers say that this drug is under the regulatory review in Europe. The drug is a combination of Lantus (insulin glargine) from Sanofi and the Lyxumia (lixisenatide. GLP-1 drug). The patients taking the insulin or a GLP-1 drug to control the blood sugar levels would be given preference.
The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has approved the Novo Nordisk drug (named as IDegLira), which is similar to iGlarLixi.
The researchers at the University of Texas Medical Branch (UTMB), Galveston have found a molecular mechanism involved in the diabetic cardiomyopathy in the patients with diabetes.
Heart diseases is the number one cause of death for the patients with diabetes. A patient with diabetes is at a higher risk of cardiovascular diseases. This is due to the damage to the heart muscle, causing a restricted blood circulation.
Researchers have identified a RNA binding protein Rbfox2. This may help the researchers in the development of better tools to manage the diabetic cardiomyopathy.
The lead author of the study was N Muge Kuyumcu-Martinez, an Assistant Professor at the University of Texas Medical Branch (UTMB), Galveston. The study was published in the Journal Cell Reports.
Researchers from the University of Pennsylvania School of Nursing have found a deficiency of 25-hydroxyvitamin D (hydroxy vitamin D) among healthy weight and Caucasian children. Authors say the study emphasize the importance of screening of 25-hydroxyvitamin D levels in all children with type 1 diabetes. The research findings were published in the Diabetes Research and Clinical Practice.
The researchers at the University of Lincoln, the United Kingdom have identified an unknown 5th molecule. The immune system attacks this molecule in the patients with type 1 diabetes.
An earlier study has found that the immune system attacks five key targets in the patients with type 1 diabetes (T1D). The earlier studies have already discovered four molecules. They are
Scientists are trying to identify the fifth molecule for the past 20 years. The earlier name for the 5th molecule was Glima. Now scientists found that it is a human protein and named as Tetraspanin-7. The Tetraspanin-7 molecule can accurately identify the risk of type 1 diabetes in the people.
The lead author of the study was Dr. Michael Christie, the University of Lincoln. The study was published in the Diabetes, the journal of the American Diabetes Association.
In an event hosted by the Jamie Reed, Copeland MP and Theresa May, Home Secretary, JDRF announced that £97m will be spent on diabetes research in the UK. The money is being provided by seven funders.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.